Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,197 · see citing works

1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults

Castro, K. G., Ward, J., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,347 · see citing works

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

Hammer, S. M., Squires, K., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J., Balfour, H. H., Deyton, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,638 · see citing works

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

Gulick, R. M., Mellors, J. W., Havlir, D. V., Eron, J. J., Gonzalez, C. J., McMahon, D. K., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,883 · see citing works

Empirical evidence of design-related bias in studies of diagnostic tests.

Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861 · see citing works

British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089 · see citing works

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065 · see citing works

Antiretroviral Therapy in Adults

Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B., Hammer, S. M., Hirsch, M., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,012 · see citing works

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993 · see citing works

1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults

(1993) · JAMA · doi:10.1001/jama.1993.03500040022009 · Cited by 964 · see citing works

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B. J., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906 · see citing works

Guidelines for Meta-analyses Evaluating Diagnostic Tests

Irwig, L., Tosteson, A. N. A., Gatsonis, C., Lau, J., Colditz, G. A., Chalmers, T. C., & Mosteller, F. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-8-199404150-00008 · Cited by 754 · see citing works

Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy

Descamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 371 · see citing works

Potential factors affecting adherence with HIV therapy

Mehta, S., Moore, R. D., & Graham, N. M. H. (1997) · AIDS · doi:10.1097/00002030-199714000-00002 · Cited by 332 · see citing works

Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens

Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297 · see citing works

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

Raboud, J., Montaner, J. S. G., Conway, B., Rae, S., Reiss, P., Vella, S., Cooper, D. A., Lange, J. M. A., Harris, M., Wainberg, M. A., et al. (1998) · AIDS · doi:10.1097/00002030-199813000-00008 · Cited by 259 · see citing works

Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection

Gulick, R. M., Mellors, J. W., Havlir, D. V., Eron, J. J., Gonzalez, C. J., McMahon, D. K., Jonas, L., Meibohm, A. R., Holder, D., Schleif, W. A., et al. (1998) · JAMA · doi:10.1001/jama.280.1.35 · Cited by 234 · see citing works

Points to consider on switching between superiority and non‐inferiority

Committee for Proprietary Medicinal Products (CPMP) (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01397-3.x · Cited by 234 · see citing works

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

Tisdale, M., Alnadaf, T., & Cousens, D. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1094 · Cited by 226 · see citing works

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

Faletto, M. B., Miller, W. H., Garvey, E. P., Clair, M. H. S., Daluge, S. M., & Good, S. S. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1099 · Cited by 224 · see citing works

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

Kempf, D. J., Rode, R. A., Xu, Y., Sun, E., Heath-Chiozzi, M. E., Valdes, J. M., Japour, A. J., Danner, S. A., Boucher, C. A., Molla, A., et al. (1998) · AIDS · doi:10.1097/00002030-199805000-00001 · Cited by 222 · see citing works

Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing

Larder, B. A., Kohli, A., Kellam, P., Kemp, S. D., Kronick, M. N., & Henfrey, R. D. (1993) · Nature · doi:10.1038/365671a0 · Cited by 198 · see citing works

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)

Gazzard, B. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00424.x · Cited by 188 · see citing works

6-year experience of prenatal diagnosis in an unselected population in Oxford, UK

Boyd, P. A., Chamberlain, P. F., & Hicks, N. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03202-4 · Cited by 160 · see citing works

Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

Harrigan, P. R., Stone, C., Griffin, P., Nájera, I., Bloor, S., Kemp, S. D., Tisdale, M., Larder, B. A., & the CNA2001 Investigative Group (2000) · The Journal of Infectious Diseases · doi:10.1086/315317 · Cited by 159 · see citing works

Antiretroviral Therapy in Adults

WISE, B. V. (1996) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.1996.tb00672.x · Cited by 137 · see citing works

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy

Miller, V., Ait‐Khaled, M., Stone, C., Griffin, P. C., Mesogiti, D., Cutrell, A. G., Harrigan, R., Staszewski, S., Katlama, C., Pearce, G. L., et al. (2000) · AIDS · doi:10.1097/00002030-200001280-00012 · Cited by 132 · see citing works

Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients

Casado, J. L., Pérez-Elı́as, M. J., Antela, A., Sabido, R., Martí-Belda, P., Dronda, F., Blázquez, J., & Quereda, C. (1998) · AIDS · doi:10.1097/00002030-199811000-00005 · Cited by 124 · see citing works

Hit HIV-1 hard, but only when necessary

Harrington, M., & Carpenter, C. C. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02388-6 · Cited by 121 · see citing works

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)

Squires, K., Gulick, R. M., Tebas, P., Santana, J., Mulanovich, V. E., Clark, R. A., Yangco, B. G., Marlowe, S. I., Wright, D. J., Cohen, C. J., et al. (2000) · AIDS · doi:10.1097/00002030-200007280-00015 · Cited by 85 · see citing works

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

Staszewski, S., Katlama, C., Harrer, T., Massip, P., Yéni, P., Cutrell, A. G., Tortell, S. M., Harrigan, R., Steel, H. M., Lanier, R., et al. (1998) · AIDS · doi:10.1097/00002030-199816000-00001 · Cited by 85 · see citing works

The case for confidence intervals in controlled clinical trials

Borenstein, M. (1994) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)90036-1 · Cited by 84 · see citing works

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults

Saag, M. S., Sönnerborg, A. B., de Torres, R. A., Lancaster, D. J., Gazzard, B., Schooley, R. T., Romero, C., Kelleher, D. L., Spreen, W. R., & LaFon, S. W. (1998) · AIDS · doi:10.1097/00002030-199816000-00002 · Cited by 84 · see citing works

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

Maguire, M. F., Gartland, M., Moore, S., Hill, A. M., Tisdale, M., Harrigan, R., & Kleim, J. (2000) · AIDS · doi:10.1097/00002030-200006160-00017 · Cited by 69 · see citing works

Suppression of Plasma Virus Load below the Detection Limit of a Human Immunodeficiency Virus Kit Is Associated with Longer Virologic Response than Suppression below the Limit of Quantitation

Raboud, J., Rae, S. L., Hogg, R. S., Yip, B., Sherlock, C. H., Harrigan, P. R., O'Shaughnessy, M. V., & Montaner, J. S. G. (1999) · The Journal of Infectious Diseases · doi:10.1086/314998 · Cited by 42 · see citing works

Amprenavir in Combination with Lamivudine and Zidovudine versus Lamivudine and Zidovudine Alone in HIV-1-Infected Antiretroviral-Naive Adults

Goodgame, J., Pottage, J. C., Jablonowski, H., Hardy, W. D., Stein, A. J., Fischl, M. A., Morrow, P., Feinberg, J., Brothers, C. H., Vafidis, I., et al. (2000) · Antiviral Therapy · doi:10.1177/135965350000500306 · Cited by 39 · see citing works

Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation

Bahado-Singh, R., Öz, A. U., Gomez, K. J., Hunter, D., Copel, J. A., Baumgarten, A., & Mahoney, M. J. (2000) · Ultrasound in Obstetrics and Gynecology · doi:10.1046/j.1469-0705.2000.00071.x · Cited by 31 · see citing works

Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection

Moyle, G. J. (2000) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200002000-00004 · Cited by 17 · see citing works

Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT 2010 Statement

Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428 · see citing works

HLA-B*5701 Screening for Hypersensitivity to Abacavir

Mallal, S. A., Phillips, E. J., Carosi, G., Molina, J., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugină, S., Козырев, О. А., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,834 · see citing works

British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008

Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089 · see citing works

Treatment for Adult HIV Infection

Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M., Carpenter, C. C. J., Fischl, M. A., Gazzard, B., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,034 · see citing works

Treatment for Adult HIV Infection

Yéni, P., Hammer, S. M., Hirsch, M., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 780 · see citing works

Understanding Equivalence and Noninferiority Testing

Walker, E., & Nowacki, A. S. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1513-8 · Cited by 751 · see citing works

Antiretroviral Treatment for Adult HIV Infection in 2002

Yéni, P., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B., Hirsch, M., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 705 · see citing works

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

Walmsley, S. L., Bernstein, B. M., King, M. S., Arribas, J. R., Beall, G. N., Ruane, P. J., Johnson, M. A., Johnson, D., LALONDE, R. G., Japour, A. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 646 · see citing works

Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach

Curran, J. W., Debas, H. T., Arya, M., Kelley, P., Knobler, S., & Pray, L. A. (2005) · Cited by 534 · see citing works

Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 521 · see citing works

Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana

Shapiro, R., Hughes, M. D., Ogwu, A., Kitch, D. W., Lockman, S., Moffat, C., Makhema, J. M., Moyo, S. M., Thior, I., McIntosh, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907736 · Cited by 519 · see citing works

Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*

Dybul, M. R., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 481 · see citing works

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

Saag, M. S., Balu, R. B., Phillips, E. J., Brachman, P. S., Martorell, C. T., Burman, W. J., Stancil, B. S., Mosteller, M., Brothers, C. H., Wannamaker, P. G., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529382 · Cited by 427 · see citing works

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Hetherington, S., McGuirk, S., Powell, G., Cutrell, A. G., Naderer, O. J., Spreen, B., Lafon, S., Pearce, G., & Steel, H. M. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 407 · see citing works

Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

Bartlett, J. A., DeMasi, R. A., Quinn, J., Moxham, C. P., & Rousseau, F. S. (2001) · AIDS · doi:10.1097/00002030-200107270-00006 · Cited by 384 · see citing works

Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy

Wit, F. W. N. M., Weverling, G. J., Weel, J. F. L., Jurriaans, S., & Lange, J. M. A. (2002) · The Journal of Infectious Diseases · doi:10.1086/341084 · Cited by 314 · see citing works

Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published Literature

Ivers, L. C., Kendrick, D. C., & Doucette, K. E. (2005) · Clinical Infectious Diseases · doi:10.1086/431199 · Cited by 313 · see citing works

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K. R., Peeples, L., Godfrey, C. C., Jahed, N. C., Myers, L., Katzenstein, D. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906768 · Cited by 312 · see citing works

Addressing the Challenges of Adherence

Bartlett, J. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200202011-00002 · Cited by 307 · see citing works

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Martínez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021589 · Cited by 291 · see citing works

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K., & Pirmohamed, M. (2004) · Pharmacogenetics · doi:10.1097/00008571-200406000-00002 · Cited by 291 · see citing works

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

Bartlett, J. A., Fath, M. J., DeMasi, R. A., Hermes, A., Quinn, J., Mondou, E., & Rousseau, F. S. (2006) · AIDS · doi:10.1097/01.aids.0000247578.08449.ff · Cited by 242 · see citing works

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210 · see citing works

Efficacy of highly active antiretroviral therapy in HIV-1 infected children

van Rossum, A. M. C., Fraaij, P. L., & de Groot, R. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00183-4 · Cited by 182 · see citing works

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

van Leeuwen, R., Katlama, C., Murphy, R. L., Squires, K., Gatell, J. M., Horban, A., Clotet, B., Staszewski, S., van Eeden, A., Clumeck, N., et al. (2003) · AIDS · doi:10.1097/00002030-200305020-00007 · Cited by 170 · see citing works

Abacavir use and cardiovascular disease events

Cruciani, M., Zanichelli, V., Serpelloni, G., Bosco, O., Malena, M., Mazzi, R., Mengoli, C., Parisi, S. G., & Moyle, G. J. (2011) · AIDS · doi:10.1097/qad.0b013e328349c6ee · Cited by 154 · see citing works

A Review of the Pharmacokinetics of Abacavir

Yuen, G. J., Weller, S., & Pakes, G. E. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847060-00001 · Cited by 152 · see citing works

Abacavir Hypersensitivity Reaction

Hewitt, R. G. (2002) · Clinical Infectious Diseases · doi:10.1086/339751 · Cited by 149 · see citing works

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects

Gallant, J. E., Rodriguez, A. E., Weinberg, W. G., Young, B., Berger, D. S., Lim, M. L., Liao, Q., Ross, L., Johnson, J., Shaefer, M. S., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/498069 · Cited by 147 · see citing works

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA

Clumeck, N., Goebel, F. D., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., Johnson, M. A., Gazzard, B., Stone, C., Athisegaran, R., et al. (2001) · AIDS · doi:10.1097/00002030-200108170-00009 · Cited by 144 · see citing works

Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte dʼIvoire

Djomand, G., Roels, T. H., Ellerbrock, T. V., Hanson, D. L., Diomandé, F. V. K., Monga, B., Maurice, C., Nkengasong, J. N., Konan-Koko, R., Kadio, A., et al. (2003) · AIDS · doi:10.1097/00002030-200317003-00002 · Cited by 139 · see citing works

A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection

Opravil, M., Hirschel, B. J., Lazzarin, A., Furrer, H., Chave, J., Yerly, S., Bisset, L. R., Fischer, M., Vernazza, P., Bernasconi, E., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/340312 · Cited by 134 · see citing works

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

DART Virology Group and Trial Team (2006) · AIDS · doi:10.1097/01.aids.0000233572.59522.45 · Cited by 129 · see citing works

Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial

Eron, J. J., Feinberg, J., Kessler, H. A., Horowitz, H. W., Witt, M. D., Carpio, F., Wheeler, D. A., Ruane, P. J., Mildvan, D., Yangco, B. G., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/380799 · Cited by 122 · see citing works

Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización febrero de 2009)

de Gesida, P. D. E., & el Sida, P. N. S. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2008.11.002 · Cited by 121 · see citing works

Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

Opravil, M., Ledergerber, B., Furrer, H., Hirschel, B. J., Imhof, A., Gallant, S., Wagels, T., Bernasconi, E., Meienberg, F., Rickenbach, M., et al. (2002) · AIDS · doi:10.1097/00002030-200207050-00009 · Cited by 111 · see citing works

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection

Quercia, R., Perno, C. F., Koteff, J. A., Moore, K. H. P., McCoig, C. C., Clair, M. S., & Kuritzkes, D. R. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001660 · Cited by 107 · see citing works

Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010)

de Gesida, P. D. E., & el Sida, P. N. S. (2010) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2010.03.002 · Cited by 99 · see citing works

Current status of antiretroviral therapy

Temesgen, Z., Warnke, D., & Kasten, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1541 · Cited by 93 · see citing works

Application of Phosphoramidate Pronucleotide Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency

McGuigan, C., Harris, S., Daluge, S. M., Gudmundsson, K. S., McLean, E. W., Burnette, T. C., Marr, H. B., Hazen, R. J., Condreay, L. D., Johnson, L. C., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0491400 · Cited by 93 · see citing works

Hyperlactataemia syndromes associated with HIV therapy

Ogedegbe, A., Thomas, D. L., & Diehl, A. M. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00654-6 · Cited by 90 · see citing works

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

Hughes, A. R., Spreen, W. R., Mosteller, M., Warren, L. L., Lai, E., Brothers, C. H., Cox, C. J., Nelsen, A. J., Hughes, S., Thorborn, D. E., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.3 · Cited by 89 · see citing works

Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily

Yuen, G. J., Lou, Y., Bumgarner, N. F., Bishop, J. P., Smith, G. A., Otto, V. R., & Hoelscher, D. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.176-182.2004 · Cited by 85 · see citing works

TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

Katlama, C., Fenske, S. W., Gazzard, B., Lazzarin, A., Clumeck, N., Mallolas, J., Lafeuillade, A., Mamet, J.-P., & Beauvais, L. (2003) · HIV Medicine · doi:10.1046/j.1468-1293.2003.00139.x · Cited by 84 · see citing works

Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine

Gerstoft, J., Kirk, O., Obel, N., Pedersen, C., Mathiesen, L., Nielsen, H. I., Katzenstein, T. L., & Lundgren, J. D. (2003) · AIDS · doi:10.1097/00002030-200309260-00005 · Cited by 79 · see citing works

Scientific and Ethical Issues in Equivalence Trials

Djulbegović, B. (2001) · JAMA · doi:10.1001/jama.285.9.1206 · Cited by 79 · see citing works

Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected Patients

Khanlou, H., Yeh, V., Guyer, B., & Farthing, C. (2005) · AIDS Patient Care and STDs · doi:10.1089/apc.2005.19.135 · Cited by 77 · see citing works

Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007)

Aldeguer, J. L. (2007) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13096750 · Cited by 76 · see citing works

A Randomized Trial of 2 Different 4‐Drug Antiretroviral Regimens versus a 3‐Drug Regimen, in Advanced Human Immunodeficiency Virus Disease

Fischl, M. A., Ribaudo, H. J., Collier, A. C., Erice, A., Giuliano, M., Dehlinger, M., Eron, J. J., Saag, M. S., Hammer, S. M., Vella, S., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377311 · Cited by 75 · see citing works

Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine

Bartlett, J. A., Johnson, J., Herrera, G., Sosa, N. R., Rodriguez, A., Liao, Q., Griffith, S. K., Irlbeck, D. M., & Shaefer, M. S. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000243092.40490.26 · Cited by 74 · see citing works

Response to Lamivudine-Zidovudine plus Abacavir Twice Daily in Antiretroviral-Naive, Incarcerated Patients with HIV Infection Taking Directly Observed Treatment

Kirkland, L. R., Fischl, M. A., Tashima, K. T., Paar, D. P., Gensler, T., Graham, N. M. H., Gao, H., Rosenzweig, J. R. C., McClernon, D. R., Pittman, G. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/338400 · Cited by 74 · see citing works

Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients

Rawlings, M. K., Thompson, M., Farthing, C., Brown, L. S., Racine, J., Scott, R. C., Crawford, K. H., Goodwin, S., Tolson, J. M., Williams, V. C., et al. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200310010-00007 · Cited by 72 · see citing works

A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity

Kumar, P. N., Rodriguez‐French, A., Thompson, M., Tashima, K. T., Averitt, D., Wannamaker, P. G., Williams, V. C., Shaefer, M. S., Pakes, G. E., Pappa, K. A., et al. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00346.x · Cited by 69 · see citing works

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine

Gulick, R. M., Meibohm, A. R., Havlir, D. V., Eron, J. J., Mosley, A., Chodakewitz, J., Isaacs, R., Gonzalez, C. J., McMahon, D. K., Richman, D. D., et al. (2003) · AIDS · doi:10.1097/00002030-200311070-00009 · Cited by 68 · see citing works

K65R with and without S68: A New Resistance Profile in Vivo Detected in Most Patients Failing Abacavir, Didanosine and Stavudine

Røge, B. T., Katzenstein, T. L., Obel, N., Nielsen, H. I., Kirk, O., Pedersen, C., Mathiesen, L., Lundgren, J. D., & Gerstoft, J. (2003) · Antiviral Therapy · doi:10.1177/135965350300800212 · Cited by 67 · see citing works

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients

Gallant, J. E., Staszewski, S., Pozniak, A., DeJesus, E., Suleiman, J. M. A. H., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., & Cheng, A. (2004) · Cited by 62 · see citing works

Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives

McGuigan, C., Hassan-Abdallah, A., Srinivasan, S., Wang, Y., Siddiqui, A. Q., Daluge, S. M., Gudmundsson, K. S., Zhou, H., McLean, E. W., Peckham, J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060776w · Cited by 61 · see citing works

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)

Saag, M. S., Tebas, P., Sension, M., Conant, M. A., Myers, R. E., Chapman, S. K., & Anderson, R. (2001) · AIDS · doi:10.1097/00002030-200110190-00009 · Cited by 61 · see citing works

Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy

Bartlett, J. A., Buda, J. J., von Scheele, B., Mauskopf, J., Davis, E. A., Elston, R., King, M. S., & Lanier, E. R. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000197070.69859.f3 · Cited by 61 · see citing works

Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing

Zhou, Y., Krebs, K., Milani, L. A., & Lauschke, V. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1944 · Cited by 60 · see citing works

Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies

Tonk, E. C. M., Gurwitz, D., der Zee, A. H. M., & Janssens, A. C. J. W. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.34 · Cited by 58 · see citing works

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients

van der Ende, M. E., Prins, J. M., Brinkman, K., Keuter, M., Veenstra, J., Danner, S. A., Niesters, H. G. M., Osterhaus, A. D. M. E., & Schutten, M. (2003) · AIDS · doi:10.1097/00002030-200317003-00008 · Cited by 57 · see citing works

Pneumocystis carinii Pneumonia in HIV-Infected Patients in the HAART Era

Pulvirenti, J., Herrera, P., Venkataraman, P., & Ahmed, N. (2003) · AIDS Patient Care and STDs · doi:10.1089/108729103322108139 · Cited by 57 · see citing works

European guidelines for the clinical management and treatment of HIV-infected adults in Europe

Clumeck, N., Wit, S. D., Hermans, P., Colebunders, R., Reiss, P., Sönnerborg, A. B., Soriano, V., Vandamme, A., & Youle, M. S. (2003) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.1097/01.aids.0000060397.18106.12 · Cited by 55 · see citing works

Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine‐Lamivudine plus Nevirapine and Zidovudine‐Lamivudine plus Abacavir

Ndembi, N., Goodall, R. L., Dunn, D. T., McCormick, A., Burke, A., Lyagoba, F., Munderi, P., Katundu, P., Kityo, C. M., Robertson, V., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/648590 · Cited by 54 · see citing works

PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events

Hughes, S. H., Hughes, A. R., Brothers, C. H., Spreen, W. R., & Thorborn, D. E. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.286 · Cited by 53 · see citing works

Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review

Chowers, M., Gottesman, B. S., Leibovici, L., Pielmeier, U., Andreassen, S., & Paul, M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp191 · Cited by 53 · see citing works

Antiretroviral-associated liver injury

Ogedegbe, A., & Sulkowski, M. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00023-0 · Cited by 53 · see citing works

Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002

Rubio, R., Berenguer, J., Miró, J. M., Antela, A., Iribarren, J. A., González, J., Guerra, L., Moreno, S., Arrizabalaga, J., Clotet, B., et al. (2002) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(02)72804-8 · Cited by 53 · see citing works

A review of drug patch testing and implications for HIV clinicians

Shear, N. H., Milpied, B., Bruynzeel, D. P., & Phillips, E. J. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb60 · Cited by 51 · see citing works

Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial

Matheron, S., Descamps, D., Boué, F., Livrozet, J., Lafeuillade, A., Aquilina, C., Troisvallets, D., Goetschel, A., Brun‐Vézinet, F., Mamet, J.-P., et al. (2003) · Antiviral Therapy · doi:10.1177/135965350300800211 · Cited by 50 · see citing works

Active-control equivalence trials and antihypertensive agents

McAlister, F. A., & Sackett, D. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00900-7 · Cited by 49 · see citing works

Designing and interpreting HIV noninferiority trials in naive and experienced patients

Hill, A. M., & Sabin, C. A. (2008) · AIDS · doi:10.1097/qad.0b013e3282f5556d · Cited by 46 · see citing works

Improving the information content of categorical clinical trial endpoints

Berger, V. W. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00233-7 · Cited by 46 · see citing works

Predictive Value of Provirus Load and DNA Human Immunodeficiency Virus Genotype for Successful Abacavir‐Based Simplified Therapy

Pellegrin, I., Caumont‐Sarcos, A., Garrigue, I., Merel, P., Schrive, M., Fleury, H. J., Dupon, M., Pellegrin, J., & Ragnaud, J. (2002) · The Journal of Infectious Diseases · doi:10.1086/345860 · Cited by 45 · see citing works

European guidelines for the clinical management and treatment of HIV-infected adults in Europe

The EACS Euroguidelines Group (2003) · AIDS · doi:10.1097/00002030-200306002-00002 · Cited by 45 · see citing works

HIV Medicine 2005

Hoffmann, C., Jk, R., & Kamps, B. S. (2005) · Cited by 45 · see citing works

Backs against the Wall: Novel and Existing Strategies Used during the 2014-2015 Ebola Virus Outbreak

Wong, G., & Kobinger, G. P. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-15 · Cited by 43 · see citing works

Simultaneous quantification of a non‐nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry

Nirogi, R. V. S., Bhyrapuneni, G., Kandikere, V. N., Mudigonda, K., Komarneni, P., Aleti, R. R., & Mukkanti, K. (2008) · Biomedical Chromatography · doi:10.1002/bmc.1125 · Cited by 43 · see citing works

γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial

Won, J. C., Kwon, H., Moon, S., Chun, S. W., Kim, C. H., Park, I. B., Kim, I. J., Lee, J., Cha, B. Y., & Park, T. S. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0099 · Cited by 46 · see citing works

Fractionated Neem Leaf Extract is Safe and Increases CD4+ Cell Levels in HIV/AIDS Patients

Mbah, A. U., Udeinya, I. J., Shu, E. N., Chijioke, C. P., Nubila, T., Udeinya, F., Muobuike, A., Mmuobieri, A., & Obioma, M. S. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180a72199 · Cited by 42 · see citing works

Tuberculosis and HIV: A Partnership Against the Most Vulnerable

Cahn, P. E., Pérez, H., Ben, G., & Ochoa, C. (2003) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/154510970300200303 · Cited by 42 · see citing works

HIV therapy in 2003

Volberding, P. A. (2003) · AIDS · doi:10.1097/00002030-200304001-00002 · Cited by 42 · see citing works

Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)

Vibhagool, A., Cahn, P. E., Schechter, M., Smaill, F., Soto-Ramírez, L. E., Carosi, G., Montroni, M., Pharo, C. E., Jordan, J. C., Thomas, N. E., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004006 · Cited by 41 · see citing works

Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine

Wit, F. W. N. M., Wood, R., Horban, A., Beniowski, M., Schmidt, R. E., Gray, G., Lazzarin, A., Lafeuillade, A., Paes, D., Carlier, H., et al. (2001) · AIDS · doi:10.1097/00002030-200112070-00010 · Cited by 41 · see citing works

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia

Mocroft, A., Phillips, A. N., Ledergerber, B., Katlama, C., Chiesi, A., Goebel, F.-D., Knysz, B., Antunes, F., Reiss, P., & Lundgren, J. D. (2006) · AIDS · doi:10.1097/01.aids.0000226954.95094.39 · Cited by 41 · see citing works

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens

Lanier, E. R., Givens, N., Stone, C., Griffin, P. C., Gibb, D. M., Walker, A. S., Tisdale, M., Irlbeck, D. M., Underwood, M., Clair, M. S., et al. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00243.x · Cited by 40 · see citing works

Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004)

AntonioIribarren, J., Labarga, P., Rubio, R., Berenguer, J., Miró, J., Antela, A., González, J., Moreno, S., Arrizabalaga, J., Chamorro, L., et al. (2004) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(04)73163-8 · Cited by 73 · see citing works

Lamivudine for the treatment of HIV

Kumar, P. N., & Patel, P. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903490418 · Cited by 39 · see citing works

Genetic Association Studies to Detect Adverse Drug Reactions: Abacavir Hypersensitivity as an Example

Hughes, A. R., Brothers, C. H., Mosteller, M., Spreen, W. R., & Burns, D. K. (2009) · Pharmacogenomics · doi:10.2217/14622416.10.2.225 · Cited by 39 · see citing works

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

Wittkop, L., Smith, C. J., Fox, Z. V., Sabin, C. A., Richert, L. E., Aboulker, J.-P., Phillips, A. N., Chêne, G., Babiker, A. G., Thiébaut, R., et al. (2010) · Clinical Trials · doi:10.1177/1740774509356117 · Cited by 38 · see citing works

Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.

Hughes, P. J., Cretton-Scott, E., Teague, A., & Wensel, T. M. (2011) · PubMed Central · Cited by 38 · see citing works

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

Keiser, P. H., Sension, M., DeJesus, E., Rodriguez, A. E., Olliffe, J. F., Williams, V. C., Wakeford, J. H., Snidow, J. W., Shachoy‐Clark, A., Fleming, J. W., et al. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-2 · Cited by 38 · see citing works

Liver Enzymes Elevation and Immune Reconstitution Among Treatment-Naïve HIV-Infected Patients Instituting Antiretroviral Therapy

Ofotokun, I., Lennox, J. L., Smithson, S. E., Lu, C., & Easley, K. A. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31811ec780 · Cited by 37 · see citing works

Antiretroviral Treatment Strategies and Immune Reconstitution in Treatment-naive HIV-Infected Patients with Advanced Disease

Soria, A., & Lazzarin, A. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000286598.00313.a6 · Cited by 37 · see citing works

Switching strategies to improve lipid profile and morphologic changes.

Barragán, P., Fisac, C., & Podzamczer, D. (2006) · PubMed · Cited by 37 · see citing works

Discovery of a Novel (+)-γ-Lactamase from Bradyrhizobium japonicum USDA 6 by Rational Genome Mining

Zhu, S., Gong, C., Song, D., Gao, S., & Zheng, G. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01398-12 · Cited by 36 · see citing works

Antiretroviral (ARV) drug resistance in the developing world.

Shekelle, P., Maglione, M., Geotz, M. B., Wagner, G. J., Wang, Z., Hilton, L. G., Carter, J. M., Chen, S. E., Tringle, C., Mojica, W., et al. (2007) · PubMed Central · Cited by 36 · see citing works

Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective

Louie, M. J., & Markowitz, M. H. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00022-0 · Cited by 36 · see citing works

Antiretroviral Recommendations May Influence the Rate of Transmission of Drug‐Resistant HIV Type 1

de Mendoza, C., Rodríguez, C., Bouza, J. M. E., Colomina, J., García, F., Leiva, P. S., Torre‐Cisneros, J., Agüero, J., Pedreira, J. D., Viciana, I., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431203 · Cited by 34 · see citing works

Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected Adults

DeJesus, E., Herrera, G., Teófilo, E., Gerstoft, J., Buendia, C. B., Brand, J. D., Brothers, C. H., Hernández, J. E., Castillo, S. A., Bonny, T., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424009 · Cited by 226 · see citing works

Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)

Vibhagool, A., Cahn, P. E., Schechter, M., Smaill, F., Soto-Ramírez, L. E., Carosi, G., Montroni, M., Pharo, C. E., Jordan, J. C., Thomas, N. E., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004006 · Cited by 41 · see citing works

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

Staszewski, S., Katlama, C., Harrer, T., Massip, P., Yéni, P., Cutrell, A. G., Tortell, S. M., Harrigan, R., Steel, H. M., Lanier, R., et al. (1998) · AIDS · doi:10.1097/00002030-199816000-00001 · Cited by 85 · see citing works

Lamivudine/Zidovudine/Abacavir

Ibbotson, T., & Perry, C. M. (2003) · Drugs · doi:10.2165/00003495-200363110-00010 · Cited by 11 · see citing works

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

Kumar, P. N., Salvato, P., LaMarca, A., DeJesus, E., Patel, P., McClernon, D. R., Florance, A. M., & Shaefer, M. S. (2009) · AIDS Research and Therapy · doi:10.1186/1742-6405-6-3 · Cited by 19 · see citing works